Jennison Associates’s Cue Biopharma CUE Stock Holding History

Jennison Associates’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-996	Closed	-$450K	–	660
2020 Q3	$450K	Sell	996 -1	-0.1%	-$576	﹤0.01%	612
2020 Q2	$733K	Buy	+997	New	+$722K	﹤0.01%	551

Other funds holding CUE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Jennison Associates's CUE Position: Q4 2020 in Review

Jennison Associates sold out of Cue Biopharma (CUE) in Q4 2020, closing a stake of 996 shares — an estimated $450K sold.

Jennison Associates first reported a position in CUE in Q2 2020 and held it in 2 quarters. The position peaked at $733K in Q2 2020. 97 funds tracked by Wall St. Rank hold CUE as of Q4 2020.

Jennison Associates reported no remaining Cue Biopharma position as of Q4 2020 after selling out during the quarter.
Jennison Associates sold 996 Cue Biopharma shares in Q4 2020, an estimated $450K.
Jennison Associates first reported a position in Cue Biopharma in Q2 2020 and held it in 2 quarters.
Jennison Associates's Cue Biopharma position peaked at $733K in Q2 2020.
97 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2020.

Based on Jennison Associates's 13F filing for Q4 2020, filed 5 Feb 2021.